Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xpovio
Pharma
With sales stagnating for Xpovio, Karyopharm slices staff by 20%
With sales stagnating for its lone approved product, Xopvio, Karyopharm Therapeutics has reduced its workforce by 20%, the company said.
Kevin Dunleavy
Aug 2, 2023 11:10am
Karyopharm hits FDA setback with Xpovio's cancer expansion bid
Mar 2, 2022 11:03am
Karyopharm plans FDA filing for Xpovio in endometrial cancer
Feb 9, 2022 8:46am
Karyopharm snags DLBCL nod for Xpovio
Jun 23, 2020 10:40am
Karyopharm's controversial Xpovio could see wider market
Mar 10, 2020 11:58am
Karyopharm's Xpovio nabs FDA nod despite checkered past
Jul 8, 2019 9:22am
